카디프 온콜로지(CRDF)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.33 (+2.31%), 시가총액 $0.11B, 52주 최저~최고 $1.48 ~ $4.45.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizum
카디프 온콜로지의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
카디프 온콜로지의 현재 주가는 $1.33 (+2.31%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
카디프 온콜로지의 시가총액은 약 $0.11B입니다.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and